Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Payables (2020 - 2025)

Historic Payables for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $851160.0.

  • Ensysce Biosciences' Payables fell 6385.35% to $851160.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $851160.0, marking a year-over-year decrease of 6385.35%. This contributed to the annual value of $1.7 million for FY2024, which is 4056.2% down from last year.
  • As of Q3 2025, Ensysce Biosciences' Payables stood at $851160.0, which was down 6385.35% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Payables ranged from a high of $17.5 million in Q4 2021 and a low of $851160.0 during Q3 2025
  • Over the past 5 years, Ensysce Biosciences' median Payables value was $2.6 million (recorded in 2023), while the average stood at $4.8 million.
  • In the last 5 years, Ensysce Biosciences' Payables surged by 210345.9% in 2021 and then crashed by 8760.57% in 2023.
  • Over the past 5 years, Ensysce Biosciences' Payables (Quarter) stood at $17.5 million in 2021, then crashed by 57.97% to $7.4 million in 2022, then tumbled by 62.03% to $2.8 million in 2023, then plummeted by 40.56% to $1.7 million in 2024, then crashed by 48.69% to $851160.0 in 2025.
  • Its Payables stands at $851160.0 for Q3 2025, versus $1.5 million for Q2 2025 and $872678.0 for Q1 2025.